Merck published a Science paper describing a new, scalable biocatalytic synthesis for enlicitide decanoate — an investigational oral PCSK9 inhibitor. The change is not cosmetic: it converts an impractical laboratory route into a process that could support commercial production, but clinical and regulatory milestones still determine whether patients will actually benefit.
How Merck’s process differs from the original chemistry
The original, first-generation synthesis for enlicitide required 63 total steps with a longest linear sequence (LLS) of 28 steps, low overall yields, and extensive chromatography—features that make large-scale manufacture prohibitively expensive. Merck’s second-generation route pruned the sequence to 43 steps and an LLS of 21, and delivered roughly a 1,000-fold improvement in yield by redesigning the order of operations and moving to crystallization-based purifications where possible.
Crucially, Merck replaced several late-stage, low-selectivity chemical transformations with enzyme-enabled steps. The tailored enzyme set works for selective fragment assembly, coupling, and macrocyclization, improving stereochemical control and reducing solvent- and reagent-intensive workups—changes that lower waste and processing complexity at scale.
Head-to-head: what changed in numbers and in practice
The quantitative differences make clear why the new route is practical rather than merely faster in the lab. The table below summarizes the most consequential contrasts and their manufacturing implications.
| Feature | First-generation route | Merck’s biocatalytic (second-generation) route |
|---|---|---|
| Total steps | 63 | 43 |
| Longest linear sequence | 28 | 21 |
| Yield | Very low overall | ~1,000× improvement |
| Purification | Heavy reliance on chromatography | Three crystalline intermediates enable crystallization, not chromatography |
| Stereochemical control | Managed by stepwise chemical control | Enzymes provide selective coupling and macrocyclization |
| Manufacturing implication | Impractical for commercial volumes | Enables industrial-scale production with lower cost and waste |
Why enlicitide’s structure demanded a novel route
Enlicitide decanoate is not a simple linear peptide: it contains eight amino acids (six are noncanonical), two macrocyclic domains, and one particularly large 37-membered ring that incorporates a non‑peptidic fragment. Those features create many stereochemical and chemoselectivity challenges that standard peptide-production platforms struggle to negotiate without combinatorial explosion in protecting-group manipulations and purification steps.
Merck addressed that by combining chemoenzymatic synthesis for the noncanonical residues with a bespoke enzyme suite for selective fragment coupling and macrocyclization. The enzymatic steps reduce off‑pathway reactions and give more predictable stereochemistry during the critical macrocyclization that defines enlicitide’s active conformation—an outcome difficult to obtain reliably using only small-molecule reagents.
Who benefits now, what still stops progress, and thresholds to watch
Patients and clinicians gain a practical route only if clinical and regulatory milestones are cleared: enlicitide showed meaningful LDL-C reductions and tolerability in Phase 2 studies, but late-stage efficacy, safety, and comparative outcomes versus injectable PCSK9 inhibitors must be confirmed. Regulators in the U.S. and EU will scrutinize not just trial results but also consistent manufacture at scale—so supply‑chain robustness and reproducible crystallization steps are operational checkpoints.
Concrete stop signals include: (1) adverse safety signals emerging in Phase 3 (especially immune or liver-related findings), (2) failure to replicate LDL‑C lowering durability versus injectables, or (3) manufacturing failures to reproduce the crystalline intermediates at commercial batch sizes. Positive thresholds to advance would be clear Phase 3 LDL‑C reductions comparable to injectables, stable tolerability across larger populations, and validated scale-up runs demonstrating the reported 1,000× yield improvement in production batches.
Quick Q&A
Q: Is enlicitide a pill that will replace injectable PCSK9 drugs? Not yet—its oral format could improve adherence and access, but that depends on Phase 3 results and regulatory approvals from agencies such as the FDA and EMA.
Q: Does Merck’s method mean any macrocyclic peptide can be made this way? No. The approach is modular and promising, but it required bespoke enzymes and process design specific to enlicitide’s chemistry; generalization will need similar development work molecule by molecule.
Q: Has the manufacturing problem been fully solved? The Science paper documents process changes that transform feasibility, including crystallization of three intermediates and enzyme-enabled steps, but scale-up validation and regulatory inspection remain necessary before commercial supply can be assumed.